Journal of Cardiovascular Pharmacology and Therapeutics · 2016 · 48 citations · 31 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDrug InteractionsPharmacovigilanceAntiplatelet TherapyCardiac MedicationsCardiovascular DiseaseCardiovascular PharmacologyCoronary Artery DiseasePharmacoepidemiologyAdverse Cardiovascular Drug EventsCochrane Review MethodologyCombination TherapyCoronary Artery Disease PharmacotherapyCyp2c19-guided Antiplatelet TherapyProton Pump InhibitionProton Pump Inhibitor InteractionsSystematic Search Patterns
BACKGROUND: Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN: The present study was performed to evaluate whether combination therapy of clopidogrel and PPIs is associated with increased risk of MACEs than with clopidogrel alone in patients with coronary artery disease. METHODS: A systematic search of MEDLINE, EMBASE, and the Cochrane Library was conducted for studies recording the occurrence of MACEs in patients with exposure to concomitant use of clopidogrel and PPIs up to February 2015. Odds ratios (ORs) were combined using a random-effects model. RESULTS: Patients receiving combination therapy with PPIs and clopidogrel were at significantly increased risk of MACEs (OR: 1.42; 95% confidence interval [CI]: 1.30-1.55). Adding a PPI to clopidogrel treatment was associated with a higher rate of MACE occurrence in rapid metabolizers (RMs, *1/*1) of CYP2C19 (OR: 1.42; 95% CI: 1.12-1.81), but there was no obviously increased rate (OR: 1.43; 95% CI: 0.89-2.28) in decreased metabolizers (with 1 or 2 loss-of-function allele). The increased risk of MACEs was similar in 4 classes of PPIs (omeprazole, lansoprazole, esomeprazole, and pantoprazole), but rabeprazole (OR: 1.03; 95% CI: 0.55-1.95) wasn't. CONCLUSION: The combination use of clopidogrel and certain types of PPIs (omeprazole, lansoprazole, esomeprazole, pantoprazole) increases the risk of MACE in patients with coronary artery disease. Only in the RMs of CYP2C19, PPIs were associated with significantly increased MACE in patients coadministered with clopidogrel.
31
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Deepak L. Bhatt, Byron Cryer, Charles F. Contant et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text
Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 729 citations
Dietmar Trenk, Willibald Hochholzer, Martin F. Fromm et al. · Journal of the American College of Cardiology · 2008 · 545 citations
Medicine, Cardiology, Pharmacology +17